Skip to main content
Equibles
RCEL logo

RCEL · AVITA Medical, Inc.

Track RCEL — free Ask ALVIS about RCEL
$4.51 +0.07 (+1.58%)
Going-concern doubt — flagged May 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's liquidity position and the Company's current forecast of operating results and cash flows, management determined there is substantial doubt about the Company's ability to continue as a going concern over the next twelve months following the date of issuance of these Consolidated Financial Statements due to the Company's debt repayment obligations, recurring losses, and historical negative cash flows.”
View the 10-Q filed May 14, 2026
Market Cap
$140.34M
Shares
30.78M

AVITA Medical, Inc. Earnings Call Transcripts

Every quarterly earnings call for AVITA Medical, Inc. (RCEL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼19.1% $8.34M −$6.26M '22 Q2 22-08-12 ▲29.5% $9.09M −$5.59M '22 Q3 22-11-14 ▼32.3% $9.46M −$5.35M '22 Q4 22-12-31 ▲39.9% $10.55M −$9.22M '23 Q1 23-05-12 ▲41% $11.75M −$10.38M '23 Q2 23-08-10 ▲50.1% $13.64M −$8.71M '23 Q3 23-11-09 ▲50.1% $14.20M −$7.07M '23 Q4 24-01-10 ▲5.3% $11.10M −$18.66M '24 Q1 24-04-11 ▲29.3% $15.20M −$15.39M '24 Q2 24-08-08 ▲43.2% $19.55M −$16.20M '24 Q3 24-11-07 ▲29.7% $18.41M −$11.59M '24 Q4 25-01-07 ▲66.7% $18.51M −$13.86M '25 Q1 25-05-08 ▲21.2% $18.42M −$9.92M '25 Q2 25-08-07 ▼12.7% $17.06M −$13.19M '25 Q3 25-11-06 ▼4.3% $17.62M −$11.62M '25 Q4 26-02-12 LATEST ▲4% $19.25M −$10.61M '26 Q1 26-05-14
Earnings call
FY26 · Q1
2026-05-14
AVITA Medical, Inc. Q1 FY2026 Earnings Call
Positive tone RECELL reimbursement recovery and demand normalization Cohealyx commercial early adoption and clinical data BARDA burn emergency preparedness contract
Revenue
$19.25M
▲ 4% YoY
Diluted EPS
$-0.35
Gross margin
81.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
AVITA Medical, Inc. Q4 FY2025 Earnings Call
Positive tone Product platform: ReCell, CoHiliX, PermeDerm Utilization and account adoption CoHiliX VAC committee reviews
Revenue
$17.62M*
▼ 4.3% YoY
Gross margin
81.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
AVITA Medical, Inc. Q3 FY2025 Earnings Call
Balanced tone RECELL product and adoption Reimbursement clarity and MAC rates Cohealyx and PermeaDerm portfolio expansion
Revenue
$17.06M
▼ 12.7% YoY
Diluted EPS
$-0.46
Gross margin
81.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
AVITA Medical, Inc. Q2 FY2025 Earnings Call
Positive tone Product portfolio expansion OrbiMed credit facility amendment Real-world evidence / clinical data
Revenue
$18.42M
▲ 21.2% YoY
Diluted EPS
$-0.38
Gross margin
81.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
AVITA Medical, Inc. Q1 FY2025 Earnings Call
Confident tone Cohealyx Launch RECELL GO mini Launch Vitiligo Pause / Risk
Revenue
$18.51M
▲ 66.7% YoY
Diluted EPS
$-0.53
Gross margin
84.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-01-07
AVITA Medical, Inc. Q4 FY2024 Earnings Call
Positive tone Cohealyx dermal matrix Revenue guidance and Q1 outlook Clinical evidence and study enrollment
Revenue
$18.41M*
▲ 29.7% YoY
Gross margin
87.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
AVITA Medical, Inc. Q3 FY2024 Earnings Call
Confident tone RECELL GO platform conversion Cohealyx dermal matrix Comprehensive treatment solution / ASP expansion
Revenue
$19.55M
▲ 43.2% YoY
Diluted EPS
$-0.62
Gross margin
83.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
AVITA Medical, Inc. Q2 FY2024 Earnings Call
Positive tone RECELL GO launch and capabilities PermeaDerm adoption VAC approval process and new accounts
Revenue
$15.20M
▲ 29.3% YoY
Diluted EPS
$-0.60
Gross margin
86.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-11
AVITA Medical, Inc. Q1 FY2024 Earnings Call
Cautious tone RECELL GO FDA review Wound care portfolio expansion Full-thickness skin defects launch
Revenue
$11.10M
▲ 5.3% YoY
Diluted EPS
$-0.73
Gross margin
86.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-01-10
AVITA Medical, Inc. Q4 FY2023 Earnings Call
Confident tone RECELL GO PMA supplement and launch Commercial revenue growth Sales force expansion and new accounts
Revenue
$14.20M*
▲ 50.1% YoY
Gross margin
87.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
AVITA Medical, Inc. Q3 FY2023 Earnings Call
Revenue
$13.64M
▲ 50.1% YoY
Diluted EPS
$-0.34
▼ 254.5% YoY
Gross margin
84.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
AVITA Medical, Inc. Q2 FY2023 Earnings Call
Revenue
$11.75M
▲ 41% YoY
Diluted EPS
$-0.41
▼ 264% YoY
Gross margin
81.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-12
AVITA Medical, Inc. Q1 FY2023 Earnings Call
Revenue
$10.55M
▲ 39.9% YoY
Diluted EPS
$-0.37
▼ 197.4% YoY
Gross margin
84.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
AVITA Medical, Inc. Q4 FY2022 Earnings Call
Revenue
$9.46M*
▼ 32.3% YoY
Gross margin
85.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
AVITA Medical, Inc. Q3 FY2022 Earnings Call
Revenue
$9.09M
▲ 29.5% YoY
Diluted EPS
$0.22
▼ 8.3% YoY
Gross margin
83.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-12
AVITA Medical, Inc. Q2 FY2022 Earnings Call
Revenue
$8.34M
▼ 19.1% YoY
Diluted EPS
$0.25
▲ 31.6% YoY
Gross margin
83.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-17
AVITA Medical, Inc. Q1 FY2022 Earnings Call
Revenue
$7.54M
▼ 14% YoY
Diluted EPS
$0.38
▲ 46.2% YoY
Gross margin
76.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-01-11
AVITA Medical, Inc. Q4 FY2021 Earnings Call
Revenue
$13.96M
▲ 173.5% YoY
Diluted EPS
$0.58
Gross margin
86.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-12
AVITA Medical, Inc. Q3 FY2021 Earnings Call
Revenue
$7.02M
▲ 38.7% YoY
Diluted EPS
$0.24
▼ 50% YoY
Gross margin
84.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-27
AVITA Medical, Inc. Q2 FY2021 Earnings Call
Revenue
$10.30M
▲ 165.8% YoY
Diluted EPS
$0.19
Gross margin
80.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-06-17
AVITA Medical, Inc. Q1 FY2021 Earnings Call
Revenue
$8.77M
▲ 126.1% YoY
Diluted EPS
$0.26
Gross margin
75.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-12
AVITA Medical, Inc. Q4 FY2020 Earnings Call
Revenue
$5.10M
▲ 56.6% YoY
Diluted EPS
$-0.26
Gross margin
83.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–22 of 22 earnings calls
Key facts CIK 1762303 CUSIP 05380C102 13F (30d) 12 filings 12 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)